Background The coronavirus disease 19 (COVID-19) pandemic has caused millions of deaths, and new treatments are urgently needed. Factors associated with a worse COVID-19 prognosis include old age (> 65 years), ethnicity, male sex, obesity, and people with comorbidities. Furthermore, vitamin D deficiency was reported as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. According to a recent clinical case series, vitamin D deficiency is a modifiable risk factor, which has the prospect of reducing hospital stay, intensive care, and fatal outcomes. Vitamin D has potent immunomodulatory properties, and its supplementation might improve important outcomes in critically ill and vitamin D-deficient COVID-19 patients. Despite the evidence that supports an association between vitamin D deficiency and COVID-19 severity, there is uncertainty about the direct link. Therefore, the aim of the trial is to assess if high-dose vitamin D supplementation has a therapeutic effect in vitamin D-deficient patients with COVID-19. Methods As the trial design, a randomized, placebo-controlled, double-blind, multi-center approach was chosen to compare a high single dose of vitamin D (140,000 IU) followed by treatment as usual (TAU) (VitD + TAU) with treatment as usual only (placebo + TAU) in patients with COVID-19 and vitamin D deficiency. Discussion Vitamin D substitution in patients with COVID-19 and vitamin D deficiency should be investigated for efficacy and safety. The study aim is to test the hypothesis that patients with vitamin D deficiency suffering from COVID-19 treated under standardized conditions in hospital will recover faster when additionally treated with high-dose vitamin D supplementation. Latest studies suggest that vitamin D supplementation in patients with COVID-19 is highly recommended to positively influence the course of the disease. With this randomized controlled trial, a contribution to new treatment guidelines shall be made. Trial registration ClinicalTrials.gov NCT04525820 and SNCTP 2020-01401
【저자키워드】 COVID-19, SARS-CoV-2, coronavirus, Vitamin D, vitamin D deficiency, 【초록키워드】 Randomized controlled trial, Treatment, coronavirus disease, coronavirus, pandemic, Respiratory failure, Trial, intensive care, Vitamin D, obesity, hospital, Comorbidities, COVID-19 severity, Acute respiratory failure, outcome, risk factor, vitamin D deficiency, outcomes, Randomized, Ethnicity, Case series, Critically ill, Patient, Tau, age, Efficacy and safety, Placebo, Vitamin, placebo-controlled, COVID-19 patients, single dose, association, COVID-19 prognosis, Evidence, Hypothesis, Male sex, deaths, double-blind, Hospital stay, followed by, old age, Support, deficiency, High-dose, Vitamin D supplementation, Factor, Trial registration, poor prognosis, therapeutic effect, immunomodulatory properties, vitamin D-deficient patients, approach, treatment guideline, IMPROVE, Course, caused, include, reported, investigated, the disease, treated, condition, faster, reducing, patients with COVID-19, treatment as usual, vitamin D-deficient patient, with COVID-19, 【제목키워드】 Study protocol, Vitamin D, Randomized, Patient, placebo-controlled, double-blind,